Congress likely to extend Breast Cancer Research semipostal sales to 2019
September 14, 2015 12:15 PM
-
The United States Congress is likely to extend sales of the Breast Cancer Research semipostal stamp to 2019. Legislation is pending in both the Senate and House.
By Bill McAllister, Washington Correspondent
A spokeswoman for Sen. Dianne Feinstein, D-Calif., says legislation to extend sales of the nation’s first semipostal stamp — the Breast Cancer Research semipostal — to 2019 is likely to win Congressional approval before Congress adjourns for the year.
“The bill to reauthorize the stamp has strong bipartisan support, and the [Senate] Homeland Security and Governmental Affairs Committee recently approved the legislation so we expect that it will move forward,” said spokeswoman Ashley Schapiti.
In May, Feinstein and Sen. Mike Enzi, R-Wyo., introduced legislation in the Senate to extend sales of the stamp, which will end this December unless Congress acts.
A companion bill, introduced by Reps. Jackie Speier, D-Calif., and Cynthia Lummis, R-Wyo., is awaiting action in a House committee.
The stamp, first issued in 1998, has proved to be the nation’s most successful semipostal, raising more than $80.4 million for breast cancer research.